 Galantamine hydrobromide is a medication that is approved for the treatment of symptoms of Alzheimers disease. In accordance with international guidelines, studies are conducted after a drug is marketed to continue to evaluate and expand the knowledge regarding its safety. This is a multi-center, open-label all people involved know the identity of the intervention, observational study individuals are observed or certain outcomes are measured - no attempt is made to affect the outcome to collect information regarding the safety and effectiveness of galantamine hydrobromide in patients with Alzheimers disease. Patients who have been prescribed galantamine hydrobromide as initial treatment with this type of medication for their Alzheimers disease or who have failed previous treatment with similar medication of this type for their Alzheimers disease will receive galantamine hydrobromide for 6 months. The individual physicians responsible for the treatment of Alzheimers disease will administer galantamine hydrobromide at doses appropriate for each patient and will continue to oversee their care. No medication will be supplied by the sponsor of this study. Safety evaluations incidence of adverse events, physical exams, vital signs and laboratory tests will be performed throughout the study. Effectiveness will be determined using standard tests and rating scales to assess mental status, functioning, thinking, behavior, judgment and language Neuropsychiatric Inventory, NPI, Mini Mental Status Exam MMSE and Clinical Global Impression-Caregiver CGI-Caregiver. Assessments will be conducted monthly for the first 3 months and at the end of 6 months of treatment. Galantamine hydrobromide treatment should be discontinued if there is no further indication of effectiveness. At the end of the study, the treating physician may continue treatment with galantamine hydrobromide in responding patients as appropriate. The study hypothesis is that galantamine hydrobromide will be effective in treating the symptoms associated with Alzheimers disease and is safe and well-tolerated. Observational study -No investigational drug administered 